These results suggest that the FA pathway and its key kinase—focal adhesion kinase (FAK)—may represent a common therapeutic target for MASLD-IRI, consistent with prior studies linking FA signaling to HSC activation [24, 25]. The gene discussed is PTK2; the disease is metabolic dysfunction-associated steatotic liver disease.